Analysts Set Expectations for TSE:GUD Q4 Earnings

Knight Therapeutics Inc. (TSE:GUD) – Stock analysts at Raymond James issued their Q4 2024 earnings estimates for Knight Therapeutics in a research report issued on Wednesday, November 13th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings per share of $0.01 for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Raymond James also issued estimates for Knight Therapeutics’ Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.

Other research analysts have also issued reports about the company. Stifel Nicolaus upgraded Knight Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the stock from C$5.75 to C$6.75 in a research report on Tuesday, August 13th. Stifel Canada raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th.

Knight Therapeutics Stock Performance

TSE:GUD opened at C$5.19 on Friday. Knight Therapeutics has a fifty-two week low of C$5.07 and a fifty-two week high of C$6.23. The company has a debt-to-equity ratio of 7.62, a quick ratio of 1.79 and a current ratio of 3.41. The company has a 50 day moving average price of C$5.71 and a 200 day moving average price of C$5.73. The stock has a market capitalization of C$525.28 million, a P/E ratio of -25.95, a PEG ratio of -1,013.50 and a beta of 0.50.

Insiders Place Their Bets

In other news, Senior Officer Amal Khouri sold 5,000 shares of Knight Therapeutics stock in a transaction dated Monday, August 19th. The stock was sold at an average price of C$5.78, for a total transaction of C$28,919.00. Also, insider Sime Armoyan bought 90,300 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average cost of C$5.13 per share, with a total value of C$463,672.44. Insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.